Cediranib
Recurrent Childhood Gliomatosis Cerebri
Pediatric Brain Tumor ConsortiumSmall moleculePhase 1/2Dormant
B
56/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 43/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Recurrent Childhood Gliomatosis Cerebri cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
HSV-1716 Pediatric Brain Tumor Consortium | Phase 1 | CC |
DEXAMETHASONE Pediatric Brain Tumor Consortium | Phase 1 | CC |
Palbociclib Pediatric Brain Tumor Consortium | Phase 1 | CC |
FLUDEOXYGLUCOSE Erik Mittra | N/A | D |
FDOPA Erik Mittra | N/A | D |
Same molecule, other indications
Cediranib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →